Status:
UNKNOWN
Comparing Haloperidol and Olanzapine in Treating Terminal Delirium
Lead Sponsor:
HCA Hospice Care
Conditions:
Delirium
Terminal Illness
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
As patients with terminal illness enter the dying phase, they may experience symptoms of restlessness, agitation, or cognitive disturbance, known as terminal delirium. In community care, pharmacologic...
Detailed Description
Our study defines "terminal delirium" as an episode of delirium that occurs during the dying phase, usually 72 hours before death. Episodes of delirium in the dying phase may be described as "terminal...
Eligibility Criteria
Inclusion
- Patient is above 21 years of age.
- Patient was diagnosed with a terminal illness and is receiving end-of-life care at home.
- Patient is assessed to be acutely dying (estimated prognosis of three days or less).
- Patient is diagnosed with delirium, as described in the DSM-V (American Psychiatric Association, 2013)
Exclusion
- Patient does not have a caregiver at home.
- Patient has a prior history of dementia, psychosis, schizophrenia or any other mental health issue followed up by psychiatrists or other specialists.
- Patient is currently receiving, or has been administered Haloperidol or Olanzapine less than a week before participating in the study.
- Patient has known allergies or adverse reactions to Haloperidol or Olanzapine.
- Patients who survive 7 days after recruitment will be excluded from the study.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04750395
Start Date
September 1 2021
End Date
May 1 2024
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HCA Hospice Care
Singapore, Singapore, 328127